secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K/A
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001193125-25-024024
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024
-----------------------------------------------------------------------------

- XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.
- Pulmokine 2023 revenue $10M (milestone) and net income $7.95M; cash $708K at year-end.
- Pro forma condensed combined balance sheet and income statements filed as Exhibit 99.4.
- Pulmokine is a biopharma developing inhaled PDGFR inhibitor for pulmonary arterial hypertension.
- Exhibits include audited FY2023, unaudited 9M2024 financials, and independent auditor consent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312525024024/0001193125-25-024024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312525024024/d935049d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-024024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer